Modalis Therapeutics Reports Second Quarter 2020 Financial Results and Operational Highlights
Successful Initial Public Offering completed and continued advancement of a broad portfolio of novel epigenetic gene modulation programs TOKYO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Modalis Therapeutics Corporation (Modalis) (TOKYO: 4883), a leading […]